[Genetic diversity of human erythroviruses. Consequences on infectious safety of plasma derivatives].
The B19 Parvovirus (B19V) has for a long time been considered as the unique human virus belonging to the genus Erythrovirus. The genetic diversity of B19V isolates has been shown to be very low. The isolation of a variant (V9 strain), with a sequence markedly distinct from that of B19V which led to attributing this classification to this family of viruses. Phylogenetic analysis of sequences of V9-related isolates indicates an organization into three well-individualized genotypes. The B19V infection can be transmitted by transfusion. In immunocompetent recipients, B19V exposure by transfusion is most often inconsequential, since a large proportion is immunized. Such an infection may have serious clinical outcome in not immunized patients with shortened red cell survival, seronegative pregnant women and immunocompromised patients. In cellular products, viral DNA detection is not performed, but a preventive strategy could be discussed for at-risk recipients. Whereas in plasma derivatives, B19V screening is performed with a threshold of 10(4)IU/ml using molecular assays. With recent data of a new classification of three genotypes within human erythrovirus, nucleic acid testing assays would be validated in accordance with the genetic variability, in order to guarantee optimal safety. Recently, a new human parvovirus (PARV4) has been discovered. The consequences on blood transfusion of this blood-borne agent and its pathogenicity are still unknown.